Search Results 1221-1230 of 17469 for Absence

1. Neurology - Clinical trials - Mayo Clinic

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

2. Neurology - Clinical trials - Mayo Clinic

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

3. Real-Time Feedback Training to Improve Gait and Posture in People with Parkinson’s Disease - Mayo Clinic

   Absence of dementia, defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria, (7) no regular use of assistance gait device such ...

4. Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE) - Mayo Clinic

   immunohistochemistry on paraffin sections). - At least moderate microvascular inflammation ([g + ptc] ≥ 2) in the absence of recurrent or de novo ...

5. Inotuzumab Ozogamicin And Post-Induction Chemotherapy In Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, And B-LLy - Mayo Clinic

   Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma. Female patients who are pregnant, since fetal toxicities ...

6. Neurology - Clinical trials

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

7. A Study Using Gallium-68 PSMA-11 and C-11 Choline PET Imaging to Detect Metastatic Prostate Cancer in Patients - Mayo Clinic

   Absence of PSA and total testosterone tests within 30 days. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team ...

8. A Study To Assess The Safety And Efficacy Of LB-P8 In Patients With PSC - Mayo Clinic

   * Small-duct PSC (in the absence of large duct PSC) * Secondary causes of sclerosing cholangitis including IgG4 associated sclerosing cholangitis * Any ...

9. A Study to Evaluate the Therapeutic Effectiveness of Rifaximin in Diabetic Gastroparesis Patients Using Bloating as the Primary Endpoint - Mayo Clinic

   ... absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; > 20% remaining at 4 hours). Exclusion ...

10. Sorafenib for Hepatopulmonary Syndrome - Mayo Clinic

    Absence of significant restriction (TLC < 70%) or obstruction (FEV1 < 80% & FEV1/FVC < 70%); Presence of cirrhosis/hepatic fibrosis and/or portal ...